miRNA-16 as a predictive factor for intracranial aneurysms in autosomal dominant polycystic kidney disease
, 1
Abstract
Introduction. Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic renal disorder. It leads to multiple extra-renal complications, with intracranial aneurysms (IA) among the most serious. Biological markers could become tools in identifying patients at risk of an IA. MicroRNAs 16 (miR-16) and 25 (miR-25) have been proposed as being markers of IAs in the general population. In the current study, we attempted to discover if they may also be considered markers of IAs in ADPKD. Material and methods. 64 renal transplant recipients with ADPKD were included. After magnetic resonance angiography of the brain, they were divided into a case group (IA+, n = 13) and a control group (IA-, n = 51). Expression of miRNAs in plasma was analysed by qRT-PCR.
Results. The expression of miR-16 was higher in the control (IA-) group. There was no statistically significant difference between the groups in terms of miR-25 expression.
Conclusions and clinical implications. MicroRNA-16 is a potential marker of IAs in renal transplant recipients with ADPKD. It may become a tool to identify patients who should undergo screening for an IA.
Keywords: autosomal dominant polycystic kidney diseasebiomarkersintracranial aneurysmkidney transplantationmicro RNA
References
- Rangan G, Alexander S, Campbell K, et al. KHA-CARI guideline recommendations for the diagnosis and management of autosomal dominant polycystic kidney disease. Nephrology. 2016; 21(8): 705–716.
- Zhou Z, Xu Y, Delcourt C, et al. Is Regular Screening for Intracranial Aneurysm Necessary in Patients with Autosomal Dominant Polycystic Kidney Disease? A Systematic Review and Meta-analysis. Cerebrovasc Dis. 2017; 44(1-2): 75–82.
- Cagnazzo F, Gambacciani C, Morganti R, et al. Intracranial aneurysms in patients with autosomal dominant polycystic kidney disease: prevalence, risk of rupture, and management. A systematic review. Acta Neurochir (Wien). 2017; 159(5): 811–821.
- Kim JY, Jung SC, Ko Y, et al. Intracranial aneurysms in patients receiving kidney transplantation for autosomal dominant polycystic kidney disease. Acta Neurochir (Wien). 2019; 161(11): 2389–2396.
- Flahault A, Trystram D, Nataf F, et al. Screening for intracranial aneurysms in autosomal dominant polycystic kidney disease is cost-effective. Kidney Int. 2018; 93(3): 716–726.
- Malhotra A, Wu X, Matouk CC, et al. MR Angiography Screening and Surveillance for Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease: A Cost-effectiveness Analysis. Radiology. 2019; 291(2): 400–408.
- Chapman AB, Devuyst O, Eckardt KU, et al. Conference Participants. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015; 88(1): 17–27.
- Li P, Zhang Q, Wu X, et al. Circulating microRNAs serve as novel biological markers for intracranial aneurysms. J Am Heart Assoc. 2014; 3(5): e000972.
- Kulesza A, Gradzik M, Kulesza A, et al. Intracranial aneurysms in renal transplant recipients with autosomal dominant polycystic kidney disease. Pol Arch Intern Med. 2020; 130(12): 1111–1113.
- Bellos I, Kontzoglou K, Perrea DN. Markers of endothelial dysfunction and arterial stiffness in patients with early-stage autosomal dominant polycystic kidney disease: A meta-analysis. Int J Clin Pract. 2020 [Epub ahead of print]: e13721.
- Matz M, Fabritius K, Lorkowski C, et al. Identification of T Cell-Mediated Vascular Rejection After Kidney Transplantation by the Combined Measurement of 5 Specific MicroRNAs in Blood. Transplantation. 2016; 100(4): 898–907.
